期刊
MOLECULAR MEDICINE REPORTS
卷 23, 期 3, 页码 -出版社
SPANDIDOS PUBL LTD
DOI: 10.3892/mmr.2021.11847
关键词
chimeric antigen receptor; C-type lectin-like molecule-1; CD371; programmed cell death 1; acute myeloid leukemia
资金
- National Natural Science Foundation of China [81730003]
- National Science and Technology Major Project [2017ZX09304021]
- National Key R&D Program of China [2017YFA0104502]
- Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)
- Jiangsu Medical Outstanding Talents Project [JCRCA2016002]
- Jiangsu Provincial Key Medical Center [YXZXA2016002]
- Research Project of Natural Science Foundation of Huai'an Jiangsu [HAB201814]
- Xuzhou Medical College [2018KJ11]
The study evaluated the effectiveness of CAR-T cells targeting CLL-1 combined with PD-1 silencing therapy for AML, suggesting it as a potential immunotherapy for relapsed or refractory AML.
The activation of chimeric antigen receptor (CAR)-T cells can lead to persistently high levels of programmed cell death 1 (PD-1) antigen and eventually causes the exhaustion of T cells. The effectiveness of CAR-T cells targeting C-type lectin-like molecule-1 (CLL-1) combined with PD-1 silencing therapy for acute myeloid leukemia (AML) was evaluated in the present study. CLL-1 levels in primary AML bone marrow samples was examined using flow cytometric analysis. We designed a CLL-1 CAR-T, containing CLL-1-specific single-chain variable fragment, CD28, OX40, CD8 hinge and TM and CD3-zeta signaling domains. CLL-1 CAR-T with PD-1 silencing was constructed. It was confirmed that CLL-1 is expressed on the surface of AML cells. CLL-1 CAR-T showed specific lysing activity against CLL-1(+) AML cells. PD-1 silencing enhanced the killing ability of CLL-1 CAR-T. Furthermore, it was found that CAR-T derived from healthy donor T cells was more effective in killing THP-1 cells (a human acute monocytic leukemia cell line) than those from patient-derived T cells. These results indicated that CLL-1 CAR-T and PD-1 knockdown CLL-1 CAR-T could be used as a potential immunotherapy to treat relapsed or refractory AML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据